Alternate Name(s):
RECOMBINANT URATE OXIDASE, SR 29142, Fasturetec
Classification:
Uricolytic agent
Original Date:
August 2005
Revised Date:
April 2022
Indications:
- Rapid treatment of acute hyperuricemia, especially in the event of impending or acute renal failure (tumor lysis syndrome)
Reconstitution and Stability:
- Available in vials containing 1.5 mg of rasburicase as a lyophilized powder
- Reconstitute with 1 mL of supplied diluent (sterile water for injection with Poloxamer 188) for a final concentration of 1.5 mg/mL
- Swirl gently to dissolve. Do not vortex or shake vial.
- Reconstituted solution may be diluted further with 0.9% NS to a total volume of 50 mL
- Reconstituted or diluted solution stable 24 hours refrigerated
- DO NOT FILTER
Compatibility:
- Solutions Compatible: 0.9% NS
- No other compatibility information. Run in dedicated line. Flush well before and after with at least 15 mL of 0.9% NS
Administration:
(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)
| SC | NO |
| IM | NO |
| IV Direct |
NO |
| IV Intermittent Infusion |
YES Large Volume Pump ONLY DO NOT FILTER |
| IV Continuous Infusion | NO |
Dosage:
(For neonatal dosages, refer to Neonatal IV Drug Manual.)
- 0.2 mg/kg/dose (max dose: 1.5mg)
Potential hazards of parenteral administration:
- Fever, headache, abdominal pain, nausea, vomiting, rash with or without erythema, dyspnea
- Injection site pain or local reaction
- Anaphylaxis, bronchospasm
Notes:
- Usually indicated for uric acid level greater than 400
- Contraindicated in patients with G-6PD deficiency (risk of hemolysis)
- Maintain anaphylaxis precautions and have medications available at the bedside
- NB: All blood samples for uric acid assay must be immediately placed on ice (heparin/green top tube) and run immediately. Rasburicase's enzymatic activity continues to degrade uric acid levels in blood sample and will give a falsely low reading. (May wish to pre-cool sample tubes.)